NCT00457587

Brief Summary

Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. Surgical resection of the tumor is the treatment of choice. However, even after complete resection more than 80 % of patients will experience recurrence of disease. Therefore, new treatment options are urgently needed. This pre-clinical study try to lay the foundations for a successful immunotherapy in patients with ACC.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
31mo left

Started Sep 2005

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress89%
Sep 2005Dec 2028

Study Start

First participant enrolled

September 1, 2005

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

April 4, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 6, 2007

Completed
20.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2028

Last Updated

August 26, 2025

Status Verified

August 1, 2025

Enrollment Period

22.3 years

First QC Date

April 4, 2007

Last Update Submit

August 24, 2025

Conditions

Adrenocortical CarcinomaCushing's Syndrome

Outcome Measures

Primary Outcomes (2)

  • To find reasonable antigens for a vaccination therapy in ACC

    day of blood sampling

  • To investigate the role of tumor-induced suppression in ACC

    NA, in vitro study

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adrenocortical carcinoma

You may qualify if:

  • patients with histological proven adrenocortical carcinoma
  • healthy persons as control group
  • Life expectancy \> 6 months

You may not qualify if:

  • autoimmune diseases
  • severe clinical condition

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dept. of Medicine I, University of Wuerzburg

Würzburg, 97080, Germany

Location

Related Publications (1)

  • Landwehr LS, Altieri B, Schreiner J, Sbiera I, Weigand I, Kroiss M, Fassnacht M, Sbiera S. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. J Immunother Cancer. 2020 May;8(1):e000469. doi: 10.1136/jitc-2019-000469.

    PMID: 32474412RESULT

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

whole blood for monocytes isolation serum urine tumor samples

MeSH Terms

Conditions

Adrenocortical CarcinomaCushing Syndrome

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsAdrenal Cortex NeoplasmsAdrenal Gland NeoplasmsEndocrine Gland NeoplasmsNeoplasms by SiteAdrenal Cortex DiseasesAdrenal Gland DiseasesEndocrine System DiseasesAdrenocortical Hyperfunction

Study Officials

  • Martin Fassnacht, MD

    University of Wuerzburg

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor for Internal Medicine and Endocrinology

Study Record Dates

First Submitted

April 4, 2007

First Posted

April 6, 2007

Study Start

September 1, 2005

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2028

Last Updated

August 26, 2025

Record last verified: 2025-08

Locations

DE(1)